Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.

Molecular diagnosis & therapy - 1 Dec 2019

Hu Minjuan, Zhang Bo, Xu Jianlin, Wang Shuyuan, Zhao Yiming, Zhang Lele, Han Baohui

Abstract excerpt

OBJECTIVES: The role of targeted therapy in patients with lung adenosquamous carcinoma (ASC) has been controversial and it was unclear whether a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could improve outcomes. This study was designed to evaluate the efficacy of different generations of EGFR TKI therapy in ASC patients with sensitive EGFR mutations. METHODS: Patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Adenosquamous

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Protein Kinase Inhibitors

Share to Sex Characteristics

Share to Survival Analysis

Source

Identifiers

PMID: 31713818
DOI: 10.1007/s40291-019-00425-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.PMID 31713818Read ↗

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.Semantic proximity Read ↗

Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung Cancer.Semantic proximity Read ↗

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.Semantic proximity Read ↗

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.Semantic proximity Read ↗

Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.Semantic proximity Read ↗

Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data.Semantic proximity Read ↗

A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861RSemantic proximity Read ↗

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.Semantic proximity Read ↗

[Clinicopathologic Features and Prognostic Implications in 72 Cases with Lung Adenosquamous Carcinoma].Semantic proximity Read ↗

Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.